01—Abstract
Summary
Summary of the 8-K filed February 22, 2024. Cited figures are marked; the original filing is the authoritative source.
On February 22, 2024, Bristol-Myers Squibb completed a $13.0 billiona public offering of senior unsecured notes across nine tranches, comprising a $500 million floating rate note due 2026 and eight fixed rate series maturing between 2026 and 2064.
The fixed rate coupons range from 4.900%b to 5.650%, and the notes were issued under the 1993 base indenture with The Bank of New York Mellon as trustee, supplemented by a Fifteenth Supplemental Indenture. The notes carry customary covenants limiting secured debt, sale/leaseback transactions, and mergers, along with customary events of default. The company intends to use a portion of the proceeds to fund the cash consideration and related fees for its proposed acquisitions of Karuna Therapeutics and RayzeBio, with any remaining proceeds going to general corporate purposes.
The offering is not contingent on those acquisitions. If the Karuna acquisition is not completed by the outside date (the later of June 30, 2025, or any extended End Date) or the company abandons it, a Special Mandatory Redemption would require repayment at 101% of principal for the floating rate notes and the 2026, 2027, 2029, and 2031 notes, totaling about $5.5 billionc. The 2034, 2044, 2054, and 2064 notes (about $7.5 billion) would remain outstanding in that scenario.
For investors, the filing shows a large, long-dated debt raise that locks in fixed financing costs for the acquisitions, with a notable tilt toward long maturities. The make-whole call provisions and the Special Mandatory Redemption feature are the key contingent terms to monitor. Because the filing predates the deal closings, the actual outcome of the acquisitions should be checked against later company disclosures.
02—Key points
Key Highlights
- Total offering of $13.0 billion across nine tranches: $0.5 billion floating rate notes and $12.5 billion of fixed rate notes.
- Fixed rate coupons range from 4.900% (2027 and 2029 notes) to 5.650% (2064 notes), with the 2054 and 2064 notes carrying the highest coupons.
- Proceeds are earmarked to fund cash consideration for the proposed Karuna Therapeutics and RayzeBio acquisitions, plus fees and expenses, with remaining proceeds for general corporate purposes.
- The offering is not contingent on the acquisitions, but a Special Mandatory Redemption at 101% is triggered if the Karuna acquisition is not consummated by the outside date or is abandoned.
- Under the redemption scenario, roughly $5.5 billion of the 2026, 2027, 2029, 2031 and floating rate notes would be redeemed, while about $7.5 billion of the 2034, 2044, 2054 and 2064 notes would remain outstanding.
- Make-whole redemption is available before each applicable par call date, and par redemption is available afterward (except for the 2026 notes, which have no par call); the floating rate notes are not callable at the company's option.
- The indenture includes customary covenants restricting secured debt, sale/leaseback transactions, and mergers or consolidations, and includes customary events of default.
03—Questions
Frequently Asked Questions
How much debt did Bristol-Myers Squibb issue, and what are the maturities?
The company issued $13.0 billion in total notes. The floating rate notes mature in February 2026, the 2026 fixed rate notes in February 2026, the 2027 notes in February 2027, the 2029 notes in February 2029, the 2031 notes in February 2031, the 2034 notes in February 2034, the 2044 notes in February 2044, the 2054 notes in February 2054, and the 2064 notes in February 2064.
Why is Bristol-Myers Squibb issuing this debt?
The company plans to use a portion of the net proceeds to pay the cash consideration for its proposed acquisitions of Karuna Therapeutics and RayzeBio, along with related fees and expenses. Any remaining proceeds will go toward general corporate purposes.
What happens to the notes if the Karuna acquisition does not close?
If the Karuna acquisition is not completed by the outside date, or the company tells the trustee it will not pursue the deal, it must redeem the floating rate notes and the 2026, 2027, 2029, and 2031 notes at 101% of principal plus accrued interest. The 2034, 2044, 2054, and 2064 notes are not subject to this mandatory redemption.
Can the company redeem the notes early, and at what price?
Before the applicable par call date, the company may redeem fixed rate notes at the greater of a make-whole price based on the Treasury rate plus a spread, or 100% of principal, plus accrued interest. On or after the par call date, the notes (other than the 2026 notes) may be redeemed at 100% of principal plus accrued interest. The floating rate notes cannot be redeemed at the company's option.
What restrictions do the notes place on the company?
The indenture includes customary covenants requiring the company to meet certain conditions before incurring secured debt, entering sale/leaseback transactions, or merging or consolidating with another entity. It also includes customary events of default.
04—Continue